Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

Technische Universität Dresden

Status: Enrolling

Conditions: Acute Myeloid Leukemia (AML)

Study type: Observational

Funder types: Other

Identifiers

NCT03188874

SAL-AML-REG-BIO

Details and patient eligibility

About

This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia.

Investigator's sites: 51 sites in Germany.

Primary objectives:

• Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry.
• Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) / time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS)
• Documentation of treatment strategy

Full description

see brief summary

Enrollment: 15,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• AML according to the WHO (World Health Organization) diagnostic criteria, including acute promyelocytic leukemia
• Age ≥ 18 years. There is no upper age limit.
• Signed written informed consent

Exclusion criteria

• there are no exclusion criteria